ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
WuXi PharmaTech, a Chinese pharmaceutical services firm, has agreed to pay $65 million to acquire NextCode Health, a company that analyzes the link between the human genome and disease susceptibility. WuXi will merge NextCode with its WuXi Genome Center to create WuXi NextCode Health with operations in China, the U.S., and Iceland. WuXi says it aims to broaden its customer base to doctors and patients “to enable anyone and any company to discover and develop health care products and services.” NextCode was spun out of DeCode Genetics when it was acquired by Amgen in 2012.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter